HEMISPHERIAN AS
Developing novel small molecule drugs targeting TET2 for aggressive cancers.
Oversigt
- 5
- Medarbejdere
- 269t NOK
- Omsætning
- 2020
- Grundlagt
Nøglebeslutningstagere
Zeno Albisser
Chief Executive Officer
Wolfram Eichner
Director
Adam Robertson
Chief Scientific Officer
Terezia Prikrylova
Chief Operating Officer
+15 flere kontakter i Funnelfeedr
Beskrivelse
Hemispherian is an innovative preclinical pharmaceutical company dedicated to redefining targeted cancer therapeutics. The core focus is developing a novel class of small molecule drugs that specifically target the TET2 enzyme. These compounds are designed as targeted therapies for particularly aggr...